Aptorum Group Ltd Class A (NIKI)

Aptorum Group Ltd Class A is a common equity listing on NASDAQ for Aptorum Group Limited, a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic products for oncology and infectious diseases. Through its subsidiaries, the company is advancing a pipeline that includes SACT-1, a repurposed drug candidate in Phase 1 testing for neuroblastoma and other cancers, and ALS-4, a repurposed small molecule in Phase 1 development for bacterial infections including Staphylococcus aureus, Mycobacterium tuberculosis, and Pseudomonas aeruginosa. Its other programs remain in preclinical development and include RPIDD, a liquid biopsy rapid pathogen diagnostic; SACT-COV19 for coronavirus disease; ALS-1 and ALS-2/3 for bacterial infections; NLS-1 for endometriosis; DLS-1+2 for NSCLC with mutation; DLS-3 for autoimmune disease; and CLS-1 for obesity. The company also markets NativusWell DOI, a dietary supplement for women undergoing menopause, and provides management services. Aptorum Group was formerly known as APTUS Holdings Limited and adopted its current name in October 2017. It was incorporated in 2010 and is headquartered in London, United Kingdom.

Jump directly to the stock analysis sections supported by the latest available data.